Set Sail for New Journeys - Haizhi Biotech's 2023 Annual Meeting Successfully Held

Set sail for a new journey

                                                                                     —— The 2023 Annual Meeting of Haizhi Biotech was successfully held

On January 18, 2023, at 1:18 PM, the first general meeting of Jiangsu Haizhi Biopharmaceutical Co., Ltd. in 2023 was successfully held.

General Manager Mr. Xu Liyou reviewedthe work of 2022.

In 2022, the company introduced talents from various sources and combined them with the existing team, significantly enhancing the sense of belonging, responsibility, and cohesion among employees. Everyone has developed a stronger sense of ownership towards the company, and the corporate culture has gradually taken shape, allowing employees to feel at home at Haizhi Biopharmaceutical. The corporate structure has also gradually formed, basically perfecting the central management structure.

In 2022, the company's revenue increased by 119% compared to 2021, with a surplus of over one million yuan. Haizhi Biotech's quality system has been further improved, enhancing quality and efficiency; five new product registrations were completed; seven contract manufacturing projects were completed, one registration project was concluded, and eight are in the reporting stage. In 2022, Haizhi Biopharmaceutical collaborated with research institutes for raw material development, initiating two development projects.

ReviewIn 2022, General Xu proposed that Haizhi Biopharmaceutical should improve and optimize processes to prevent communication gaps, reduce waste of packaging materials, raw materials, and samples. The R&D and production departments collaborated to optimize processes and arrange production lines more reasonably.

OutlookIn 2023, Haizhi Biotech plans to double its revenue compared to 2022, with profits exceeding ten million; in R&D, it plans to certify six Class II medical devices, initiate nine, and formally start two Class III medical device registration applications; further promote CDMO services, assisting partners in certifying eight Class II medical devices and initiating over ten.

In 2023, the company will improve its incentive mechanism to enhance employees' sense of responsibility and mission towards the company, truly embodying the concept that "Haizhi Biopharmaceutical is everyone's". Together we will start a business and share the results. General Xu announced that the company will introduce an equity incentive plan! Additionally, the distribution mechanism will be further optimized, generally based on contributions to the company, determining proportions according to positions and roles, while weighting individual performance assessments, allowing all employees to share in the company's profits!

Representatives of Haizhi Biotech's management, center directors, and outstanding employee representatives gave speeches. Combiningthe R&D project reserves of 2022, OEM customer resource reserves, and the construction of the investment team, everyone is very confident in achieving the overall goal proposed by General Manager Xu Liyou for 2023!

Group photo of participating employees

The outstanding employees of 2022 came from the R&D Quality Center and the Production Center: Lv Hui, Zhen Yuhong, Liu Xiao, and Guo Changhui. We look forward to having outstanding employees from the Marketing Center in 2023.

Group photo of the management team and outstanding employees

The outstanding team of 2022 came from the Production Center. They overcame many difficulties together with other departments, such as the Shanghai pandemic control in the first half of the year, logistics restrictions, high temperatures and power limits in the middle of the year, and pandemic control at the end of the year, ensuring quality and quantity in completing production tasks.

Group photo of the outstanding team